4D Molecular Therapeutics Ownership | Who Owns 4D Molecular Therapeutics?


OverviewForecastRevenueFinancialsChart

4D Molecular Therapeutics Ownership Summary


4D Molecular Therapeutics is owned by 103.86% institutional investors, 3.91% insiders. Ra capital management is the largest institutional shareholder, holding 10.35% of FDMT shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.96% of its assets in 4D Molecular Therapeutics shares.

FDMT Ownership Benchmark


TypeName% Inst% Insiders% Retail
Stock4D Molecular Therapeutics103.86%3.91%-7.78%
SectorHealthcare Stocks 49.73%8.84%41.43%
IndustryBiotech Stocks 47.04%8.74%44.21%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Ra capital management5.10M10.35%$107.01M
Blackrock4.90M9.94%$102.79M
Vr adviser4.40M8.93%$92.36M
Goldman sachs group4.13M8.39%$86.78M
Deep track capital, lp4.06M8.24%$85.25M
Bvf inc/il3.92M7.96%$82.33M
Janus henderson group3.20M6.49%$67.11M
Vanguard group2.53M5.13%$53.07M
State street2.08M4.22%$43.64M
Polar capital1.74M3.54%$36.62M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Vr adviser4.40M5.88%$92.36M
Deep track capital, lp4.06M2.54%$85.25M
Bvf inc/il3.92M2.31%$82.33M
Decheng capital347.83K2.24%$7.30M
Eagle health investments lp462.91K1.70%$9.72M
Novo1.40M1.47%$29.39M
Ra capital management5.10M1.42%$107.01M
Redmile group1.07M1.36%$22.53M
Casdin capital800.00K1.28%$16.79M
Sphera funds management242.53K0.69%$5.09M

Top Buyers

HolderShares% AssetsChange
Goldman sachs group4.13M0.01%1.08M
Deep track capital, lp4.06M2.54%1.03M
Blackrock4.90M0.00%612.35K
Panagora asset management354.86K0.04%252.79K
Vanguard group2.53M0.00%188.24K

Top Sellers

HolderShares% AssetsChange
Viking global investors lp---2.93M
Braidwell lp369.46K0.24%-683.03K
Lmr partners llp---487.53K
Opaleye management---345.75K
Ubs group67.14K0.00%-307.05K

New Positions

HolderShares% AssetsChangeValue
Hudson bay capital management lp113.30K0.01%113.30K$2.38M
Gsa capital partners llp64.88K0.10%64.88K$1.36M
Twinbeech capital lp58.62K0.02%58.62K$1.23M
Corebridge financial26.81K0.00%26.81K$562.70K
Mirae asset global etfs24.75K0.00%24.75K$519.26K

Sold Out

HolderChange
Innealta capital-4.00
Rothschild investment-5.00
Nelson, van denburg & campbell wealth management group-8.00
Federated hermes-27.00
Allworth financial lp-28.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 2024140-4.11%57,700,8380.63%1030.77%76-7.32%4210.53%
Jun 30, 2024146-6.41%57,338,9551.87%1160.89%82-21.15%382.70%
Mar 31, 202415633.33%56,284,67532.64%1140.97%10462.50%3732.14%
Dec 31, 20231171.74%42,433,9381.23%1081.10%641.59%28-15.15%
Sep 30, 20231158.49%41,916,6621.06%990.85%63-11.27%3373.68%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv1.54M2.96%-
iShares Russell 2000 ETF1.31M2.52%-2.94K
Janus Henderson Global Life Sciences D1.03M1.97%-710.00
Janus Henderson Global Life Sciences1.02M1.96%-10.84K
SPDR® S&P Biotech ETF996.42K1.92%11.02K
Eventide Healthcare & Life Sciences I881.16K1.70%105.04K
Polar Capital Healthcare Opports Inc790.16K1.52%-
Janus Global Life Science AUSD750.90K1.44%6.30K
Janus Henderson Glb Life Scn I2 USD750.90K1.44%3.46K
Vanguard Institutional Extnd Mkt Idx Tr587.21K1.13%-1.94K

Recent Insider Transactions


DateNameRoleActivityValue
Sep 16, 2024Bizily Scott Chief Legal OfficerSell$8.16K
Aug 19, 2024Bizily Scott Chief Legal OfficerSell$7.50K
Jul 16, 2024Bizily Scott Chief Legal OfficerSell$47.44K
Jul 11, 2024Bizily Scott Chief Legal OfficerSell$49.90K
Jul 10, 2024Kirn David Chief Executive OfficerSell$290.60K

Insider Transactions Trends


DateBuySell
2024 Q4--
2024 Q3-6
2024 Q2-6
2024 Q1-13
2023 Q4-2

FDMT Ownership FAQ


Who Owns 4D Molecular Therapeutics?

4D Molecular Therapeutics shareholders are primarily institutional investors at 103.86%, followed by 3.91% insiders and -7.77% retail investors. The average institutional ownership in 4D Molecular Therapeutics's industry, Biotech Stocks , is 47.04%, which 4D Molecular Therapeutics exceeds.

Who owns the most shares of 4D Molecular Therapeutics?

4D Molecular Therapeutics’s largest shareholders are Ra capital management (5.1M shares, 10.35%), Blackrock (4.9M shares, 9.94%), and Vr adviser (4.4M shares, 8.93%). Together, they hold 29.22% of 4D Molecular Therapeutics’s total shares outstanding.

Does Blackrock own 4D Molecular Therapeutics?

Yes, BlackRock owns 9.94% of 4D Molecular Therapeutics, totaling 4.9M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 102.79M$. In the last quarter, BlackRock increased its holdings by 612.35K shares, a 14.29% change.

Who is 4D Molecular Therapeutics’s biggest shareholder by percentage of total assets invested?

Vr adviser is 4D Molecular Therapeutics’s biggest shareholder by percentage of total assets invested, with 5.88% of its assets in 4.4M 4D Molecular Therapeutics shares, valued at 92.36M$.

Who is the top mutual fund holder of 4D Molecular Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of 4D Molecular Therapeutics shares, with 2.96% of its total shares outstanding invested in 1.54M 4D Molecular Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools